Loading…
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-41M | $-38M | $-24M | -39.0% | - | - |
| 2024 | $0M | $-22M | $-22M | $-20M | -46.0% | -100.0% | - |
| 2023 | $0M | $-19M | $-20M | $-18M | -9684.2% | 2.7% | - |
| 2022 | $0M | $-18M | $-18M | $-16M | -631.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0.07 | 0.07 | 0 | 0 |
| Cost Of Revenue | 0.01 | 0 | 0 | 0 |
| Gross Profit | 0.06 | 0.07 | 0 | 0 |
| Operating Expense | 17.92 | 19.16 | 22.49 | 41.77 |
| Operating Income | -17.85 | -19.08 | -22.49 | -41.77 |
| EBITDA | -17.78 | -18.70 | -22.15 | -41.37 |
| EBIT | -18.18 | -19.08 | -22.49 | -41.77 |
| Pretax Income | -18.21 | -19.56 | -21.75 | -37.92 |
| Net Income | -18.21 | -19.56 | -21.75 | -37.92 |
| Net Income Common Stockholders | -18.21 | -19.56 | -22.37 | -37.92 |
| Total Expenses | 17.93 | 19.16 | 22.49 | 41.77 |
| Interest Expense | 0.03 | 0.03 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 |
| Research And Development | 11.27 | 12.77 | 15.61 | 18.33 |
| Selling General And Administration | 6.65 | 6.38 | 6.99 | 23.43 |
| Normalized EBITDA | -17.54 | -18.28 | -22.19 | -42.06 |
| Normalized Income | -17.96 | -19.14 | -21.79 | -38.61 |
| Basic EPS | -37.91 | -14.12 | -1.22 | -1.05 |
| Diluted EPS | -37.91 | -14.12 | -1.22 | -1.05 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -0.24 | -0.42 | 0.04 | 0.69 |
| Total Unusual Items Excluding Goodwill | -0.24 | -0.42 | 0.04 | 0.69 |
| Net Income From Continuing Operation Net Minority Interest | -18.21 | -19.56 | -21.75 | -37.92 |
| Reconciled Depreciation | 0.39 | 0.38 | 0.34 | 0.40 |
| Reconciled Cost Of Revenue | 0.01 | 0 | 0 | 0 |
| Net Interest Income | -0.03 | -0.03 | 0.90 | 3.29 |
| Net Income From Continuing And Discontinued Operation | -18.21 | -19.56 | -21.75 | -37.92 |
| Total Operating Income As Reported | -17.85 | -19.08 | -22.49 | -41.77 |
| Diluted Average Shares | 0.48 | 1.39 | 18.36 | 36.21 |
| Basic Average Shares | 0.48 | 1.39 | 18.36 | 36.21 |
| Diluted NI Availto Com Stockholders | -18.21 | -19.56 | -22.37 | -37.92 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0.62 | 0 |
| Net Income Including Noncontrolling Interests | -18.21 | -19.56 | -21.75 | -37.92 |
| Net Income Continuous Operations | -18.21 | -19.56 | -21.75 | -37.92 |
| Other Income Expense | -0.32 | -0.45 | -0.17 | 0.56 |
| Other Non Operating Income Expenses | -0.08 | -0.03 | -0.20 | -0.13 |
| Special Income Charges | 0 | 0 | 0 | 0.76 |
| Other Special Charges | 0 | 0 | 0 | -0.76 |
| Gain On Sale Of Security | -0.24 | -0.42 | 0.04 | -0.07 |
| Net Non Operating Interest Income Expense | -0.03 | -0.03 | 0.90 | 3.29 |
| Total Other Finance Cost | 0 | 0.03 | -0.90 | -3.29 |
| Interest Expense Non Operating | 0.03 | 0.03 | 0 | 0 |
| Interest Income Non Operating | 0 | 0 | 0 | 0 |
| Other Operating Expenses | 0.01 | 0 | -0.11 | 0 |
| General And Administrative Expense | 6.65 | 6.38 | 6.99 | 23.43 |
| Other Gand A | 6.65 | 6.38 | 6.99 | 23.43 |
| Salaries And Wages | 0.61 | 0.29 | 0 | 0 |
| Operating Revenue | 0.07 | 0.07 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Benitec Biopharma Inc.this co. | BNTC | $416M | - | 2.22 | -39.0% | -4.75 |
| Fulgent Genetics, Inc. | FLGT | $427M | - | 0.41 | -5.5% | -1.98 |
| Vanda Pharmaceuticals Inc. | VNDA | $424M | - | 1.27 | -67.4% | -1.16 |
| Strata Critical Medical, Inc. | SRTA | $424M | - | 1.52 | 14.8% | -64.52 |
| Lexeo Therapeutics, Inc. | LXEO | $421M |
| - |
| 1.68 |
| -40.5% |
| -2.27 |
| Neurogene Inc. | NGNE | $414M | - | 1.55 | -34.1% | -1.53 |
| Emergent BioSolutions Inc. | EBS | $413M | 8.59 | 0.80 | 10.1% | 3.79 |
| Community Health Systems, Inc. | CYH | $404M | 0.83 | -0.27 | -60.8% | 7.88 |
| Enanta Pharmaceuticals, Inc. | ENTA | $402M | - | 3.18 | -126.5% | -6.01 |
| Peer Median | - | 4.71 | 1.40 | -37.3% | -1.76 | |